Home / Health / Novo Nordisk Launches Oral Ozempic in Q2
Novo Nordisk Launches Oral Ozempic in Q2
5 Feb
Summary
- Oral Ozempic pill doses approved by FDA are 1.5, 4, and 9 mg.
- The oral Ozempic will be available in the second quarter of this year.
- The pill is also approved to lower cardiovascular risk in adults with type 2 diabetes.
Novo Nordisk will introduce oral doses of semaglutide under the brand name Ozempic pill starting in the second quarter of this year. The U.S. Food and Drug Administration has granted approval for 1.5 mg, 4 mg, and 9 mg strengths.
This new oral formulation is designed to enhance patient and healthcare provider recognition of available type 2 diabetes treatments. It aims to address patient inquiries about an oral alternative, noting that Rybelsus tablets have been available since 2019 in different strengths.
Beyond diabetes management, the Ozempic pill is also indicated to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk. The FDA's approval for these new doses was based on studies for Rybelsus. The company awaits a regulatory decision on a 25 mg dose by the end of 2026.
